Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors

Emicizumab (ACE910), a recombinant humanized bispecific monoclonal antibody, provides factor VIII (FVIII) cofactor bridging function to restore hemostasis in people with hemophilia A. In a phase 1 trial involving 18 Japanese patients with severe hemophilia A, once-weekly subcutaneous administration...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Shima, Midori, Hanabusa, Hideji, Taki, Masashi, Matsushita, Tadashi, Sato, Tetsuji, Fukutake, Katsuyuki, Kasai, Ryu, Yoneyama, Koichiro, Yoshida, Hiroki, Nogami, Keiji
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2017
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728143/
https://ncbi.nlm.nih.gov/pubmed/29296836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017006684
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados